Law360, New York (May 04, 2011, 12:31 PM ET) -- Actelion Ltd. vowed Wednesday to appeal a California jury verdict ordering it to pay Asahi Kasei Pharma Corp. $547 million in damages for interfering with an Asahi drug development licensing agreement in order to preserve its monopoly on pulmonary arterial hypertension treatments.
Actelion said in a statement that it was disappointed with the state court jury’s decision handed down Friday, and it vowed to file appropriate additional post-trial motions and appeal the entire judgment. Late Tuesday the jury also awarded punitive damages of $30 million against...
Actelion Vows To Appeal Jury Verdict In Asahi Fight
To view the full article, take a free trial now.
